Japan silent heart attack market is estimated to grow at a CAGR of around 7.2% during the forecast period. The possibility of a heart attack in the geriatric population is relatively high as compared to the young population. As per the UN, out of the total 126 million population, about 27% population of the country was above 65 years in 2019. It is estimated that the population will reduce to 124 million in 2025 and the share of the geriatric population in the total population is will be higher as compared to 2019. The growth of the silent heart attack market in Japan is being supported by innovative and advanced product launches by the key regional market players. The home monitoring has demonstrated a 90% reduction in inappropriate shocks and a 73% reduction in related hospitalization rates in Japan. Therefore, Japan is contributing significantly to the growth of the silent heart attack market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-silent-heart-attack-market
Japan silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Surgery is most commonly required to increase blood flow through a blocked artery. Therefore, angioplasty and bypass surgery are significantly used for the management of blocked arteries and improve blood flow to the heart.
The companies which are contributing to the growth of the Japan silent heart attack market include AstraZeneca PLC, Bayer AG, Terumo Corp., F. Hoffmann-La Roche Ltd., OrbusNeich Medical Technologies, and GlaxoSmithKline Plc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Japan Silent Heart Attack Market- Segmentation
By Diagnosis
- Electrocardiography (ECG)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Surgery
- By End-User
- Hospital & Clinics
- Ambulatory Surgical Centers
A full report of Japan Silent Heart Attack Market is available at: https://www.omrglobal.com/industry-reports/japan-silent-heart-attack-market
Company Profiles
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Boston Scientific Corp.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Medtronic PLC
- Novartis AG
- OrbusNeich Medical Technologies
- Pfizer Inc.
- Siemens AG
- Takeda Pharmaceutical Co. Ltd.
- Terumo Corp.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
